{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:16:19Z","timestamp":1772824579992,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003121","name":"Ferdowsi University of Mashhad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.taap.2023.116470","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:15:58Z","timestamp":1679022958000},"page":"116470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study"],"prefix":"10.1016","volume":"466","author":[{"given":"Atefeh","family":"Biabangard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Asoodeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Moosavi Baigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116470_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.09.018","article-title":"Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release","volume":"315","author":"Aghdam","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2023.116470_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3389\/fimmu.2018.02391","article-title":"MUC1 mucin: a putative regulatory (checkpoint) molecule of T cells","volume":"9","author":"Agrawal","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.taap.2023.116470_bb0020","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2013.10.018","article-title":"Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas","volume":"458","author":"Amin","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2023.116470_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2015.10.044","article-title":"Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin","volume":"220","author":"Arabi","year":"2015","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.taap.2023.116470_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcs.2014.01.019","article-title":"Potential angiotensin I converting enzyme inhibitory peptides from gluten hydrolysate: biochemical characterization and molecular docking study","volume":"60","author":"Asoodeh","year":"2014","journal-title":"J. Cereal Sci."},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control.Rel."},{"issue":"3","key":"10.1016\/j.taap.2023.116470_bb0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2023.116470_bb0050","article-title":"Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study","volume":"1-15","author":"Biabangard","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.taap.2023.116470_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115671","article-title":"Delivery of doxorubicin loaded P18 conjugated-poly (2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast cancer","volume":"428","author":"Bolat","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2005.02.009","article-title":"Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese","volume":"104","author":"Chiu","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2023.116470_bb0065","series-title":"Characterization of Nanoparticles Intended for Drug Delivery. Methods in Molecular Biology","article-title":"Zeta potential measurement","volume":"vol 697","author":"Clogston","year":"2011"},{"issue":"16","key":"10.1016\/j.taap.2023.116470_bb0070","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1080\/07391102.2016.1264892","article-title":"Multi-spectroscopic and molecular modeling studies of interaction between two different angiotensin I converting enzyme inhibitory peptides from gluten hydrolysate and human serum albumin","volume":"35","author":"Darban","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"12","key":"10.1016\/j.taap.2023.116470_bb0075","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2217\/nnm-2017-0069","article-title":"PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells","volume":"12","author":"Darban","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.taap.2023.116470_bb0080","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.2147\/IJN.S220754","article-title":"Co-delivery of dihydroartemisinin and HMGB1 siRNA by TAT-modified cationic liposomes through the TLR4 signaling pathway for treatment of lupus nephritis","volume":"14","author":"Diao","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"2\u20133","key":"10.1016\/j.taap.2023.116470_bb0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc. Res."},{"issue":"4","key":"10.1016\/j.taap.2023.116470_bb0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"Goel","year":"2010","journal-title":"Int. J. Ayurveda Res."},{"issue":"9","key":"10.1016\/j.taap.2023.116470_bb0095","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/ph14090835","article-title":"Challenges of current anticancer treatment approaches with focus on liposomal drug delivery systems","volume":"14","author":"Gyanani","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.taap.2023.116470_bb0100","article-title":"Liposomal doxorubicin targeting mitochondria: a novel formulation to enhance anti-tumor effects of Doxil\u00ae in vitro and in vivo","volume":"62","author":"Haftcheshmeh","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.taap.2023.116470_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21691401.2017.1304403","article-title":"A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery","volume":"46","author":"Haghiralsadat","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"6","key":"10.1016\/j.taap.2023.116470_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biol. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.taap.2023.116470_bb0115","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/0929866527666200413100120","article-title":"Liposome circulation time is prolonged by CD47 coating","volume":"27","author":"Hayat","year":"2020","journal-title":"Protein Pept. Lett."},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00926084","article-title":"Influence of liposome charge and composition on their interaction with human blood serum proteins","volume":"120","author":"Hern\u00e1ndez-Caselles","year":"1993","journal-title":"Mol. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.taap.2023.116470_bb0125","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0005-2736(01)00357-1","article-title":"In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach","volume":"1513","author":"Iden","year":"2001","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"3","key":"10.1016\/j.taap.2023.116470_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/1567201814666170712122508","article-title":"Doxorubicin-loaded micelle targeting MUC1: a potential therapeutic for MUC1 triple negative breast cancer treatment","volume":"15","author":"Khondee","year":"2018","journal-title":"Curr. Drug Deliv."},{"issue":"4","key":"10.1016\/j.taap.2023.116470_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40005-016-0260-1","article-title":"Liposomal drug delivery system","volume":"46","author":"Kim","year":"2016","journal-title":"J. Pharm. Investig."},{"issue":"6","key":"10.1016\/j.taap.2023.116470_bb0145","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2174\/1871520620666200101150640","article-title":"The effect of phase transition temperature on therapeutic efficacy of liposomal bortezomib","volume":"20","author":"Korani","year":"2020","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"issue":"4","key":"10.1016\/j.taap.2023.116470_bb0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00228148","article-title":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR","volume":"8","author":"Laskowski","year":"1996","journal-title":"J. Biomol. NMR"},{"issue":"2","key":"10.1016\/j.taap.2023.116470_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40005-018-0398-0","article-title":"Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin","volume":"49","author":"Lee","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.taap.2023.116470_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2018.01.033","article-title":"A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers","volume":"275","author":"Liang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2023.116470_bb0165","first-page":"1","article-title":"Introductory chapter: drug delivery concepts","author":"Maiti","year":"2017","journal-title":"Adv. Technol. Deliv. Ther."},{"issue":"1","key":"10.1016\/j.taap.2023.116470_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-020-03334-9","article-title":"Anti-Epcam aptamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma","volume":"15","author":"Mashreghi","year":"2020","journal-title":"Nanoscale Res. Lett."},{"issue":"8","key":"10.1016\/j.taap.2023.116470_bb0175","first-page":"2054","article-title":"5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells","volume":"46","author":"Moosavian","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.taap.2023.116470_bb0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1014434732752","article-title":"Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity","volume":"19","author":"Moreira","year":"2002","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.taap.2023.116470_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-409X(99)00041-1","article-title":"The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs","volume":"40","author":"Nagayasu","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.taap.2023.116470_bb0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/ct049941i","article-title":"An efficient linear-scaling Ewald method for long-range electrostatic interactions in combined QM\/MM calculations","volume":"1","author":"Nam","year":"2005","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.taap.2023.116470_bb0195","first-page":"1","article-title":"Molecular dynamics simulations of the SARS-CoV-2 spike protein and variants of concern: structural evidence for convergent adaptive evolution","author":"Neto","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.taap.2023.116470_bb0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2018.04.018","article-title":"Liposomal CpG-ODN: an in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers","volume":"119","author":"Nikoofal-Sahlabadi","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.taap.2023.116470_bb0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-62703-541-5_5","article-title":"Linker technologies for antibody\u2013drug conjugates","author":"Nolting","year":"2013","journal-title":"Antibody-drug Conjug."},{"issue":"7","key":"10.1016\/j.taap.2023.116470_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02865-1","article-title":"RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer\u2019s disease","volume":"37","author":"Pinheiro","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2023.116470_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116036","article-title":"Targeted delivery of doxorubicin by Thermo\/pH-responsive magnetic nanoparticles in a rat model of breast cancer","volume":"446","author":"Pourradi","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116470_bb0220","series-title":"Nanostructures for Cancer Therapy. Chapter 8 - Nanotechnological approaches toward cancer chemotherapy","first-page":"211","article-title":"Nanotechnological approaches toward cancer chemotherapy","author":"Rajagopalan","year":"2017"},{"issue":"6","key":"10.1016\/j.taap.2023.116470_bb0225","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0006-3495(65)86759-5","article-title":"Stereochemical criteria for polypeptide and protein chain conformations: II. Allowed conformations for a pair of peptide units","volume":"5","author":"Ramakrishnan","year":"1965","journal-title":"Biophys. J."},{"issue":"5","key":"10.1016\/j.taap.2023.116470_bb0230","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/ijms17050701","article-title":"Design and application of antimicrobial peptide conjugates","volume":"17","author":"Reinhardt","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.taap.2023.116470_bb0235","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"issue":"suppl_2","key":"10.1016\/j.taap.2023.116470_bb0240","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.taap.2023.116470_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111589","article-title":"Preparation and characterization of PEGylated liposomal doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma","volume":"200","author":"Shahraki","year":"2021","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"22","key":"10.1016\/j.taap.2023.116470_bb0250","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jp801293a","article-title":"Spontaneous formation of functionalized dendrimer-stabilized gold nanoparticles","volume":"112","author":"Shi","year":"2008","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.taap.2023.116470_bb0255","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.09.055","article-title":"Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment","volume":"329","author":"Sonju","year":"2021","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.taap.2023.116470_bb0260","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nucmedbio.2009.02.004","article-title":"[186Re] liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model","volume":"36","author":"Soundararajan","year":"2009","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"10.1016\/j.taap.2023.116470_bib286","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.taap.2023.116470_bb0265","first-page":"67","article-title":"Molecular simulation and systems biology","author":"Swope","year":"2006","journal-title":"Netw. Mod. Appl."},{"issue":"2\u20133","key":"10.1016\/j.taap.2023.116470_bb0270","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0925-4439(99)00055-1","article-title":"MUC1 and cancer","volume":"1455","author":"Taylor-Papadimitriou","year":"1999","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"4","key":"10.1016\/j.taap.2023.116470_bb0275","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.juro.2012.06.011","article-title":"Correlation of magnetic resonance imaging tumor volume with histopathology","volume":"188","author":"Turkbey","year":"2012","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.taap.2023.116470_bb0280","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active targeting strategies using biological ligands for nanoparticle drug delivery systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.taap.2023.116470_bb0285","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0014-3057(92)90273-5","article-title":"Calculation of the mean-square radius of gyration for polymer chains with side-groups","volume":"28","author":"Zhiping","year":"1992","journal-title":"Eur. Polym. J."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:02:50Z","timestamp":1758574970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":57,"alternative-id":["S0041008X23001084"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116470","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116470"}}